Trials / Terminated
TerminatedNCT00230334
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Steven E. Coutre · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gleevec |
Timeline
- Start date
- 2003-06-12
- Primary completion
- 2006-12-29
- Completion
- 2007-05-01
- First posted
- 2005-09-30
- Last updated
- 2021-05-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00230334. Inclusion in this directory is not an endorsement.